A Phase II Trial of Pemetrexed Plus Oxaliplatin in Patients With Advanced Biliary Tract Cancer After Failure of Gemcitabine Plus Cisplatin-based Chemotherapy
PemOx showed modest efficacy and manageable TRAEs in patients with aBTC after the failure of first line GP-based chemotherapy, although the primary endpoint was not met.
Authors
- Hyehyun Jeong (ORCID: https://orcid.org/0000-0001-7277-6463)
- Jaekyung Cheon (ORCID: https://orcid.org/0000-0001-8439-1739)
- Jwa Hoon Kim (ORCID: https://orcid.org/0000-0002-0838-0111)
- In Hae Park (ORCID: https://orcid.org/0000-0001-7894-8772)
- Kyu‐pyo Kim (ORCID: https://orcid.org/0000-0001-7848-5923)
- Chung Ryul Oh (ORCID: https://orcid.org/0000-0003-1788-4538)
- Baek‐Yeol Ryoo (ORCID: https://orcid.org/0000-0002-9052-833X)
- Changhoon Yoo (ORCID: https://orcid.org/0000-0002-1451-8455)
- Hye Won Ryu (ORCID: https://orcid.org/0000-0001-5329-6026)
- Heung-Moon Chang
Institutions
- Ulsan College (KR)
- Chungnam National University (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- Chung-Ang University Hospital (KR)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-08-28
- DOI
- https://doi.org/10.21873/anticanres.17756
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00